SG Americas Securities LLC Sells 15,336 Shares of Bausch Health Companies Inc. (NYSE:BHC)

SG Americas Securities LLC lowered its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,038,275 shares of the company’s stock after selling 15,336 shares during the quarter. SG Americas Securities LLC owned 0.56% of Bausch Health Companies worth $16,632,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BHC. CIBC Asset Management Inc raised its position in Bausch Health Companies by 3.5% in the fourth quarter. CIBC Asset Management Inc now owns 290,967 shares of the company’s stock worth $2,342,000 after purchasing an additional 9,960 shares in the last quarter. Prudential PLC acquired a new position in Bausch Health Companies in the fourth quarter worth about $735,000. Redwood Investment Management LLC raised its position in Bausch Health Companies by 3.7% in the fourth quarter. Redwood Investment Management LLC now owns 401,495 shares of the company’s stock worth $3,220,000 after purchasing an additional 14,184 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Bausch Health Companies by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 11,599,131 shares of the company’s stock worth $93,025,000 after buying an additional 111,363 shares in the last quarter. Finally, Salem Investment Counselors Inc. acquired a new stake in shares of Bausch Health Companies during the first quarter worth approximately $32,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Stock Up 0.6 %

BHC stock traded up $0.05 during midday trading on Friday, reaching $8.32. The company’s stock had a trading volume of 1,155,077 shares, compared to its average volume of 3,058,721. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $11.46. The stock has a market cap of $3.00 billion, a PE ratio of -6.71 and a beta of 0.77. The business’s 50-day simple moving average is $6.50 and its 200-day simple moving average is $7.27.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. During the same period last year, the firm earned $0.81 earnings per share. As a group, equities analysts forecast that Bausch Health Companies Inc. will post 3.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BHC shares. Jefferies Financial Group dropped their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Truist Financial dropped their price objective on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a report on Thursday, July 25th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, September 25th. Piper Sandler cut shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Finally, Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, Bausch Health Companies presently has an average rating of “Hold” and a consensus target price of $7.33.

Insiders Place Their Bets

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the sale, the executive vice president now directly owns 435,198 shares in the company, valued at approximately $2,702,579.58. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 8.12% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.